Top Markets
#1 NKN NKN +160.00%
#2 Bluwhale Bluwhale +34.89%
#3 Codatta Codatta +30.46%
#4 SAFEcoin SAFEcoin +28.54%
#5 Saakuru Saakuru +24.27%
#6 StakeStone StakeStone +19.16%
#7 Particle Network Particle Network +18.79%
#8 Yooldo Games Yooldo Games +15.38%
#9 Arcblock Arcblock +14.06%
#10 Ski Mask Dog Ski Mask Dog +13.94%
Coin of the day
NKN NKN
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
Classifica tra le azioni #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Prezzo delle azioni
$0.15
Capitalizzazione di mercato
$4.96M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
CA
Scambia Intellipharmaceutics International Inc. (IPCIF)

Categoria

Healthcare
Rapporto P/S per Intellipharmaceutics International Inc. (IPCIF)
Rapporto P/S al March 2026 TTM: 75.52
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Intellipharmaceutics International Inc., il rapporto P/S attuale (TTM) è 75.52. Alla fine del 2021, era pari a 53.73.
Storico del rapporto P/S per Intellipharmaceutics International Inc. da 1999 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
2026 (TTM) 75.52 114.31%
2022 35.24 -34.41%
2021 53.73 2,358.50%
2020 2.19 -5.37%
2019 2.31 151.70%
2018 0.92 -80.84%
2017 4.79 -85.55%
2016 33.15 171.91%
2015 12.19 61.06%
2014 7.57 -85.08%
2013 50.74 -86.99%
2012 390.00 315.68%
2011 93.82 375.52%
2010 19.73 0.00%
2009 0.00 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
2006 0.00 0.00%
2005 0.00 0.00%
2004 0.00 0.00%
2003 0.00 0.00%
2002 0.00 -100.00%
2001 22.45K 2.75%
2000 21.84K 14,851.44%
1999 146.10 0.00%
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
3.55 -95.30%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.90 -86.89%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
5.40 -92.85%
US
UCB SA UCB SA
UCB SA
UCB.BR
6.14 -91.87%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.90 -82.92%
NL